G-1 (CAS 881639-98-1): Illuminating GPR30 Signaling in Cardiac and Immune Research

Introduction: The Evolving Landscape of GPR30/GPER1 Research

The rapid, non-genomic actions of estrogen have long intrigued researchers, particularly as their physiological and pathological roles diverge from those mediated by classical nuclear estrogen receptors (ERα and ERβ). Central to these rapid effects is the G protein-coupled estrogen receptor (GPR30/GPER1), a membrane-bound receptor distinct in both localization and signaling. G-1 (CAS 881639-98-1), a highly selective GPR30 agonist, has emerged as a transformative tool to dissect these pathways, providing unmatched receptor specificity and experimental reliability. In this article, we provide a deep-dive into G-1’s mechanistic profile, highlight its impact in cardiovascular and immune modulation, and critically examine its experimental applications—offering a perspective not yet addressed in prior literature.

G-1: Chemical Properties and Unique Selectivity

G-1 is a crystalline solid with a molecular weight of 412.28 (C₂₁H₁₈BrNO₃), characterized by its selective binding to GPR30 (K_i ≈ 11 nM) while exhibiting negligible affinity for ERα and ERβ, even at micromolar concentrations. This selectivity is crucial for parsing genuine GPR30-mediated effects from those of nuclear estrogen receptors. G-1 is highly soluble in DMSO (≥41.2 mg/mL) but insoluble in water and ethanol, with practical stock solutions prepared at >10 mM in DMSO and stored at -20°C for short-term use (see full product details and ordering information at APExBIO's G-1 (CAS 881639-98-1), a selective GPR30 agonist).

Mechanism of Action of G-1: GPR30 Activation and Downstream Signaling

Upon binding to GPR30, G-1 triggers a cascade of intracellular events distinct from classical estrogenic signaling. Notably, G-1 induces rapid elevation of intracellular calcium (EC₅₀ ≈ 2 nM) and PI3K-dependent nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3). These convergent pathways orchestrate diverse biological outcomes, including:

• Inhibition of breast cancer cell migration via cytoskeletal remodeling and cell signaling checkpoints, with potent IC₅₀ values in SKBr3 (0.7 nM) and MCF7 (1.6 nM) cells.
• Attenuation of cardiac fibrosis and improvement of contractility in heart failure models, mediated by the normalization of β₁-adrenergic receptor and upregulation of β₂-adrenergic receptor expression.
• Immune modulation through the normalization of CD4⁺ T lymphocyte function post-hemorrhagic shock, as evidenced by recent translational studies.

This multifaceted signaling profile enables researchers to interrogate GPR30-mediated PI3K signaling pathways and intracellular calcium signaling via GPR30 with unprecedented precision.

G-1 in Cardiovascular Research: Beyond Cardiac Fibrosis Attenuation

Cardioprotection in Preclinical Heart Failure Models

Chronic administration of G-1 in ovariectomized female Sprague-Dawley rats with heart failure resulted in marked reductions in brain natriuretic peptide, robust inhibition of cardiac fibrosis, and improved cardiac contractility. Mechanistically, G-1 treatment normalized the expression of β₁-adrenergic receptors and promoted β₂-adrenergic receptor upregulation, offering a path to reversing maladaptive cardiac remodeling. These findings have established G-1 as a gold standard for GPR30 activation in cardiovascular research, going beyond the descriptive scope of prior articles to explore the therapeutic mechanisms underlying these effects.

Integrating GPR30 Signaling with Endocrine and Paracrine Control

While previous reviews (such as "G-1 (CAS 881639-98-1): Advancing GPR30 Agonist Research") have touched on G-1's role in cardiac fibrosis and breast cancer migration, our discussion extends these insights by examining how GPR30-mediated rapid estrogen signaling interfaces with classical adrenergic and paracrine pathways. This integration is crucial for understanding the translatability of G-1-based interventions to clinical scenarios of heart failure and post-infarction remodeling.

G-1 and Immune Modulation: Mechanistic Insights from Hemorrhagic Shock Models

One of the most compelling, yet underexplored, applications of G-1 lies in immune normalization following trauma or shock. A seminal study demonstrated that activation of GPR30 by G-1 (and ERα by PPT) restored the proliferative capacity and cytokine production of splenic CD4⁺ T lymphocytes following hemorrhagic shock, primarily through inhibition of endoplasmic reticulum stress (ERS). Notably, ERβ agonists (like DPN) failed to recapitulate these effects, while GPR30 antagonism abolished the benefits of estradiol and G-1. These findings underscore the non-redundant, rapid, and non-genomic role of GPR30 in immune homeostasis and inflammation, which is distinct from the slower, nuclear receptor-mediated pathways.

By directly linking GPR30 activation to ERS attenuation and T cell function, this research highlights G-1's value as a mechanistic probe for dissecting immune dysfunction post-trauma—a perspective not fully explored in previous content.

Comparative Analysis: G-1 Versus Alternative Estrogenic Agonists

Dissecting Selectivity and Experimental Precision

Unlike traditional estrogenic agonists (E2, PPT, DPN), which may cross-activate multiple receptor subtypes, G-1's selectivity for GPR30 enables precise attribution of observed effects to GPR30 signaling. This is especially critical in experimental settings where confounding by ERα/ERβ activation can obscure mechanistic interpretation. As highlighted in "A Selective GPR30 Agonist for Rapid Estrogen Signaling", G-1 enables accurate dissection of non-genomic estrogenic pathways; however, our article further elucidates how this selectivity translates to actionable outcomes in cardiovascular and immunological contexts, specifically in models of immune normalization and ERS attenuation.

Experimental Best Practices and Technical Considerations

For optimal experimental outcomes, prepare G-1 stock solutions in DMSO at concentrations >10 mM, employing gentle warming and ultrasonic baths to enhance solubility. Avoid prolonged storage, and always aliquot to minimize freeze-thaw cycles. These practical guidelines, also discussed in "Reliable GPR30 Research with G-1", are essential for maintaining compound activity and ensuring reproducibility in cell-based and in vivo assays.

Advanced Applications: G-1 in Breast Cancer Research and Beyond

Inhibition of Breast Cancer Cell Migration

G-1’s ability to inhibit breast cancer cell migration—demonstrated by low-nanomolar IC₅₀ values in SKBr3 and MCF7 cells—offers a robust model for studying metastatic processes and for screening anti-migratory agents. Mechanistically, this effect is mediated via GPR30-driven changes in cytoskeletal dynamics and cellular adhesion, distinct from the actions of nuclear estrogen receptors.

Expanding the Frontier: GPR30 in Immune and Endocrine Disorders

Recent translational research, including the referenced Scientific Reports study, has revealed that GPR30 activation by G-1 normalizes immune function post-hemorrhagic shock by inhibiting ERS in CD4⁺ T lymphocytes. This positions G-1 as a unique tool for investigating immune-endocrine crosstalk, with implications for trauma, infection, and autoimmune disorders. Such applications move beyond the focus of earlier reviews like "G-1 Driving Precision in Rapid Estrogen Signaling", by highlighting G-1’s utility not just in mechanistic dissection, but also in translational and preclinical modeling of immune recovery.

Conclusion and Future Outlook

G-1 (CAS 881639-98-1), available from APExBIO, stands out as the definitive selective GPR30 agonist for delineating rapid estrogenic signaling in cardiovascular, oncological, and immunological research. Its unique chemical and pharmacological properties, combined with validated experimental protocols, position it as a cornerstone reagent for exploring GPR30-mediated PI3K signaling pathways, intracellular calcium signaling, and immune normalization after physiological stressors.

This article adds novel depth by integrating cutting-edge mechanistic and translational insights—especially in immune modulation and ERS attenuation—expanding the scope beyond previous overviews and practical guides. For researchers seeking to advance the boundaries of GPR30 activation in cardiovascular research, inhibition of breast cancer cell migration, and immune homeostasis, G-1 (CAS 881639-98-1), a selective GPR30 agonist is the essential, validated choice.